Cabergoline for the Treatment of Chronic Pain Due to Endometriosis
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Endometriosis is dependent on angiogenesis (the sprouting of new blood vessels) for its
growth and maintenance, but the side effects of currently approved angiogenesis inhibitors
make these agents inappropriate for use in reproductive-age patients. This obstacle will be
overcome by performing a randomized, double blind clinical trial aimed at repurposing an
existing drug, cabergoline, as a safe, alternative angiogenesis inhibitor for adolescents and
young women with endometriosis. This trial proposes a novel, non-hormonal, non-surgical
therapeutic approach aimed at alleviating the pain and suffering associated with this common
chronic disease that currently has limited treatment options.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Children's Hospital Boston Children’s Hospital